These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 20704848)

  • 21. Current developments in cancer vaccines and cellular immunotherapy.
    Ribas A; Butterfield LH; Glaspy JA; Economou JS
    J Clin Oncol; 2003 Jun; 21(12):2415-32. PubMed ID: 12805342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer immunogene therapy.
    Yoshizawa H; Kagamu H; Gejyo F
    Arch Immunol Ther Exp (Warsz); 2001; 49(5):337-43. PubMed ID: 11798131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dendritic cells as natural adjuvants and modulators of immune response in cancer immunotherapy.
    Alli RS; Khar A
    Indian J Biochem Biophys; 2002 Dec; 39(6):363-7. PubMed ID: 22905392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting dendritic cells for priming cellular immune responses.
    Gogolák P; Réthi B; Hajas G; Rajnavölgyi E
    J Mol Recognit; 2003; 16(5):299-317. PubMed ID: 14523943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The immunogenicity of dendritic cell-derived exosomes.
    Quah BJ; O'Neill HC
    Blood Cells Mol Dis; 2005; 35(2):94-110. PubMed ID: 15975838
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts).
    Gattoni A; Parlato A; Vangieri B; Bresciani M; Derna R
    Clin Ter; 2006; 157(4):377-86. PubMed ID: 17051976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dendritic cells as vectors for immunotherapy of tumor and its application for gastric cancer therapy.
    Wu Y; Wang L; Zhang Y
    Cell Mol Immunol; 2004 Oct; 1(5):351-6. PubMed ID: 16285894
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumor vaccination: where we stand.
    Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S
    Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The sympathetic nerve--an integrative interface between two supersystems: the brain and the immune system.
    Elenkov IJ; Wilder RL; Chrousos GP; Vizi ES
    Pharmacol Rev; 2000 Dec; 52(4):595-638. PubMed ID: 11121511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liposomal vaccines--targeting the delivery of antigen.
    Altin JG; Parish CR
    Methods; 2006 Sep; 40(1):39-52. PubMed ID: 16997712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New understanding of immunological mechanisms.
    Saalmüller A
    Vet Microbiol; 2006 Oct; 117(1):32-8. PubMed ID: 16701965
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ADP-ribosylating bacterial enzymes for the targeted control of mucosal tolerance and immunity.
    Lycke N
    Ann N Y Acad Sci; 2004 Dec; 1029():193-208. PubMed ID: 15681758
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
    Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT
    Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-Gal-mediated targeting of human B lymphoma cells to antigen-presenting cells: a potential method for immunotherapy using autologous tumor cells.
    Manches O; Plumas J; Lui G; Chaperot L; Molens JP; Sotto JJ; Bensa JC; Galili U
    Haematologica; 2005 May; 90(5):625-34. PubMed ID: 15921377
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of the accessory cells involved in suppressor T cell induction.
    Noma T; Usui M; Dorf ME
    J Immunol; 1985 Mar; 134(3):1374-80. PubMed ID: 3155765
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine.
    Ko HJ; Lee JM; Kim YJ; Kim YS; Lee KA; Kang CY
    J Immunol; 2009 Feb; 182(4):1818-28. PubMed ID: 19201833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity.
    Broz ML; Binnewies M; Boldajipour B; Nelson AE; Pollack JL; Erle DJ; Barczak A; Rosenblum MD; Daud A; Barber DL; Amigorena S; Van't Veer LJ; Sperling AI; Wolf DM; Krummel MF
    Cancer Cell; 2014 Dec; 26(6):938. PubMed ID: 28898680
    [No Abstract]   [Full Text] [Related]  

  • 38. Grand challenges in molecular antigen-presenting cell-biology.
    Kurts C; Wagner H
    Front Immunol; 2011; 2():8. PubMed ID: 22566799
    [No Abstract]   [Full Text] [Related]  

  • 39. BRAIN TUMOR: ITS PRESENTING SYMPTOMS.
    Courville CB
    Cal West Med; 1929 Aug; 31(2):100-3. PubMed ID: 18741112
    [No Abstract]   [Full Text] [Related]  

  • 40. Novel tumor immunotherapy: Targeting dysfunctional antigen presenting cells.
    Wei S; Kryczek I; Zou L; Curiel T; Cheng P; Zou W
    Discov Med; 2005 Oct; 5(29):489-92. PubMed ID: 20704848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.